Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Neoplasms 13Prostatic Neoplasms 11Nasopharyngeal Carcinoma 11Lung Neoplasms 11Carcinoma, Hepatocellular 11Multiple Myeloma 10Leukemia, Myeloid, Acute 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 6Uterine Cervical Neoplasms 5Recurrence 5Glioblastoma 5Esophageal Squamous Cell Carcinoma 5Colonic Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Lymphoma, Follicular 4

Interventions

ribociclib 1exemestane 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Drug Therapy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Anatomic Stage II Breast Cancer AJCC v8 × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡